Olivier Brandicourt appointed as new CEO of Bayer HealthCare
Leverkusen, September 30, 2013 – Olivier Brandicourt (57) has been appointed Chairman of the Board of Management of Bayer HealthCare and member of the Bayer AG Executive Council effective November 1, 2013. Since March 2013, Professor Wolfgang Plischke has led Bayer HealthCare on an interim basis in addition to his existing duties as a Bayer AG Board Member.
"With Olivier Brandicourt we have found a strong leader with outstanding international experience and a successful track record in the healthcare industry. I am convinced that he can significantly contribute to the further growth of our healthcare business," said Bayer Group CEO Dr. Marijn Dekkers.
Brandicourt has 25 years of international experience in the pharmaceutical industry, including executive responsibilities in France, the United States, Canada and the United Kingdom. He has been a member of the Executive Leadership Team of Pfizer Inc., New York, USA, for the last three years. Until recently he was President and General Manager of the Emerging Markets and Established Products Business Units. Before that he held senior operational positions as President of the Global Specialty Business Unit, and until 2012 he was head of the Global Primary Care Business Unit. Furthermore, he previously held senior regional and country management positions at Pfizer and positions across a range of disciplines including medical and marketing at Warner-Lambert/Parke-Davis.
"I am looking forward to joining the Bayer team. With a clear focus on research and development as well as a passion and dedication to improving people's lives, Bayer has an excellent track record in bringing innovation to the market," said Olivier Brandicourt.
Olivier Brandicourt holds a medical degree with a subspecialty in infectious diseases and tropical medicine, as well as a master's degree in biology from Paris 12 University, France. After completing his studies, Brandicourt spent two years in the Republic of Congo as a doctor and eight years with the Institute for Infectious and Tropical Diseases at Pitié-Salpêtrière Hospital in Paris, spending half this time in West and Central Africa working on malaria research. Brandicourt is an Honorary Fellow of the Royal College of Physicians in London, UK, and a member of the Children's Aid Society's Board of Trustees in New York. He is married with three grown-up children.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2012, the Group employed 110,000 people and had sales of €39.7 billion. Capital expenditures amounted to €1.9 billion, R&D expenses to €3.0 billion. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.